Are “manograms” a viable option in prostate cancer screening and risk assessment?

For several years, Dr. Jelle Barentz in the Netherlands has been a prominent advocate for the idea that we might be able to use imaging methodologies (prostate “manograms”, like breast mammograms for women) to screen for risk of prostate cancer — either along with or instead of PSA testing. … READ MORE …

Gadolinium contrast and mpMRI scans

In his latest epistle to the medical community on the MedPage Today web site, prostate cancer patient Howard Wolinsky writes about the need (or lack of need) for the use of gadolinium-containing contrast agents associated with the conduct of multiparametric MRI (mpMRI) scans. … READ MORE …

What did we learn at the AUA this year?

The annual meeting of the American Urological Association (AUA) is one at which a great deal of information is exchanged, but a lot of that information is of limited utility to patients. … READ MORE …

MRI and MRI-guided biopsies — a new Cochrane review

Cochrane reviews are structured, systematic, focused reviews of evidence in the field of medicine that either support or do not support specific forms of diagnosis and management of patients with or suspected of having particular disorders. … READ MORE …

Howard Wolinsky dodges another MRI and another biopsy

Under the heading “Rats, my PSA went up. Do I need another bleeping biopsy?” Howard Wolinsky provides us with the latest “lowdown” on his 8-year-long prostate cancer journey on active surveillance. … READ MORE …

Can MRI data improve decision-making about the need for a biopsy?

Last week we noted that adding MRI data to the Partin tables and to the Kattan/MSKCC nomograms did not seem to improve the accuracy of prognosis of outcomes after radical prostatectomy. … READ MORE …

Did you get an MRI scan as part of your clinical work-up for prostate cancer risk?

A report in the journal Urology (the so-called “Gold Journal”) from a team of researchers at Yale School of Medicine has shown that having a prostate MRI as part of the work-up for a patient initially diagnosed with low-risk prostate cancer roughly doubled the chance that such a patient was initially managed on “observation”. … READ MORE …